Science 37® and CMIC Announce Partnership to Advance Decentralized Clinical Trials in Japan/APAC and Speed Drug Development
October 27 2021 - 8:00AM
Science 37, the Operating System for today’s more agile clinical
trials, and CMIC HOLDINGS Co., Ltd. (“CMIC”), the largest CRO in
Japan today announced a partnership to further decentralized
clinical trials and to help speed the development of treatments. In
this collaboration, CMIC will use Science 37’s clinical trial
Operating System and its end-to-end technology platform to help
orchestrate workflows, generate evidence and harmonize data for
global decentralized studies—helping speed study timelines.
In a traditional site-based model, biopharmaceutical sponsors
are limited by geography and physical location, making it difficult
for patients to participate. Decentralized trials, enabled by
technology, can alleviate these burdens—helping to drive
efficiency, reduce costs and enabling more patients to
participate.
“Science 37 is the first and largest decentralized clinical
trial platform company in the U.S. providing telemedicine, eSource
and other digital solutions to investigator sites and patients in
the West,” said Yoshihito Kondo, Executive Vice President of
Clinical Operation at CMIC CO., Ltd. “Science 37’s decentralized
technologies and methods bring research directly to patients,
helping to reduce patient burden and will speed therapies to
market. With our partnership and utilizing the Science 37 Operating
System and technology platform, we are able to more effectively
orchestrate the user experience and workflows for patients,
telemedicine investigators and mobile nurses, generate requisite
evidence and harmonize data all in one place. This partnership will
also allow for the smooth conduct of global trials including Japan
and/or APAC using a unified platform, which will help with CMIC’s
efforts to lead the growth of the developing decentralized clinical
trial movements in the East. This will ultimately result in
accelerating the development of treatments that impact patient
lives, which is of the most importance to CMIC.”
Through this partnership, CMIC becomes part of the Science 37
CRO Certified network, designed to empower CROs with access,
training, and commercial support to successfully deliver
decentralized clinical studies at scale.
“Partnering with CMIC, a leading Japanese contract research
organization, enables us to continue to expand our
technology-centered Operating System in Asia and aligns with our
mission to accelerate research and empower patient and provider
access,” said David Coman, Chief Executive Officer of Science 37.
“Our technology platform will provide CMIC with the capability to
more effectively execute decentralized studies with our Operating
System which enables access to patient communities, telemedicine
investigators, remote coordinator and connected device
networks.”
About CMIC groupCMIC Group was founded in 1992
as the first Contract Research Organization (CRO) in Japan. Today
CMIC Group is the largest clinical CRO in Japan with a global
footprint, providing comprehensive services in drug development,
clinical site management, manufacturing, regulatory consulting and
contract sales & marketing solutions. We can help
pharmaceutical, biotech and medical device companies to enter the
Japanese market, to conduct clinical trials in Asia, or to bridge
drug development and manufacturing needs in the US, Europe, Japan
and broader Asia. CMIC Group has over 7,000 employees and 25 sites
globally. For more information about CMIC Group and services,
please visit our website. https://en.cmicgroup.com/
About Science 37Science 37, Inc.’s mission is
to enable universal access to clinical research—making it easier
for patients and providers to participate from anywhere and helping
to accelerate the development of treatments that impact patient
lives. As a pioneer of decentralized clinical trials, the Science
37 Clinical Trial Operating System (OS) supports today’s more agile
clinical research designs with its full stack, end-to-end
technology platform and specialized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators and connected devices. Configurable to enable any
study type, the Science 37 OS enables up to 15x faster enrollment,
28% better retention and 3x more diverse patient population with
industry-leading workflow orchestration, evidence generation and
data harmonization. For more information, visit
https://www.science37.com.
MEDIA INQUIRIES:CMIC HOLDINGS Co., LTD. PR groupE-mail:
pr@cmic.co.jp
Margie KoomanScience 37Phone: (984) 377-3737Email:
pr@science37.com
INVESTOR RELATIONS:Caroline PaulGilmartin
GroupInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024